- VRTX -0.51%
Is Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) the Leading Gene Therapy Stock to Buy Now?
Yahoo Finance · 6 days ago
Moderna
Search results
Vertex Pharmaceuticals invests in scientific innovation to create transformative medicines for people with serious diseases.
- 483.04Add to watchlist-2.49 (-0.51%)At close: Fri. Jun 7, 2024 4:00 PM EDT · Nasdaq Real Time Price (USD) · Market closed
- Open484.45High486.42Low480.10
- Mkt Cap124.65BP/E (TTM)31.35Div & YieldN/A & N/A
- Prev. Close485.5352 Wk. Low331.8752 Wk. High486.43
What analysts are sayingTop storiesRelated stocks
Vertex Pharmaceuticals strikes at the core of serious diseases to change people's lives – learn about our mission, values and recognition.
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
At Vertex, we invest in scientific innovation to create transformative medicines for people with serious diseases.
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
Dec 8, 2023 · Vertex leads global development, manufacturing and commercialization of CASGEVY with support from CRISPR Therapeutics. In conjunction with the FDA approval of CASGEVY, Vertex will make a $200 million milestone payment to CRISPR, which will be capitalized and amortized to cost of sales.
Jan 30, 2024 · BOSTON -- (BUSINESS WIRE)--Jan. 30, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 3 program for the selective NaV1.8 inhibitor, VX-548, in the treatment of moderate-to-severe acute pain.
The Investor Relations website contains information about Vertex Pharmaceuticals's business for stockholders, potential investors, and financial analysts.
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older. Read More. Apr 23 2024. Vertex and TreeFrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex’s Cell Therapies for Type 1 Diabetes. Read More.
Dec 13, 2023 · BOSTON -- (BUSINESS WIRE)--Dec. 13, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 2 dose-ranging study of the selective NaV1.8 inhibitor VX-548 in people with painful diabetic peripheral neuropathy (DPN).
